[1]曹 庄,李赛赛,曹人元,等.国家医保谈判药品落地情况研究——基于5市17种国谈抗癌药使用及报销数据的分析[J].卫生经济研究,2022,39(7):53-56,59.
　CAO Zhuang,LI Saisai,CAO Renyuan,et al.Research on the Accessibility of National Medical Insurance Negotiation Drugs ——An Analysis Based on the Usage and Reimbursement Data of 17 National Negotiated Anticancer Drugs in Five Cities[J].Journal Press of Health Economics Research,2022,39(7):53-56,59.
点击复制

国家医保谈判药品落地情况研究
——基于5市17种国谈抗癌药使用及报销数据的分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年7期
页码:
53-56,59
栏目:
药械管理
出版日期:
2022-06-30

文章信息/Info

Title:
Research on the Accessibility of National Medical Insurance Negotiation Drugs
——An Analysis Based on the Usage and Reimbursement Data of 17 National Negotiated Anticancer Drugs in Five Cities
作者:
曹 庄1; 李赛赛1; 曹人元1; 马 勇1
1.首都医科大学国家医疗保障研究院，北京 100037
Author(s):
CAO Zhuang;  LI Saisai;  CAO Renyuan;  MA Yong
National Institute of Healthcare Security, Capital Medical University, Beijing 100037, China
关键词:
国家医保谈判药品; 可获得性; 可及性
Keywords:
national medical insurance negotiation drugs;  affordability;  accessibility
分类号:
R19
文献标志码:
A
摘要:
通过对比5市17种国谈抗癌药的使用及报销数据，分析国谈药落地情况及其影响因素。为促进国谈药落地，要提高医疗机构配备国谈药的积极性；加快推动“双通道”管理政策落地，发挥药店供药作用；完善多层次医疗保障制度，提高国谈药报销水平；加强医保基金监管，确保安全、合理用药。
Abstract:
By comparing the use and reimbursement data of 17 anticancer drugs, the implementation of the drugs and their influencing factors were analyzed. In order to promote the implementation of national negotiated drugs, it is necessary to increase the enthusiasm of medical institutions to deploy national negotiated drugs, accelerate the implementation of the dual-channel management policy, give play to the role of pharmacies in drug supply, improve the multi-level medical security system, improve the reimbursement level of national negotiated drugs, strengthen the supervision of medical insurance funds , and ensure safe and rational use of drug.

参考文献/References:

[1] 金华.药品准入谈判实现共赢的四个关键环节[J].中国医疗保险，2017（8）：22-23.
[2] 吴梦月.处方信息共享平台助力处方外流[J].中国药店，2017（12）：48-49.
[3] 谢远涛，杨娟.医疗保险全覆盖对抑制因病致贫返贫的政策效应[J].北京师范大学学报（社会科学版），2018（4）：141-156.

相似文献/References:

[1]路 云,张闪闪,李世勇.江苏省基本药物制度实施效果评价与思考[J].卫生经济研究,2017,(10):45.
[2]刘 昉,李翠翠,马 健,等.基层用药公平可及性评价研究[J].卫生经济研究,2018,(04):46.
[3]吴玉霞,徐 伟,蔡功杰,等.基本药物可获得性影响因素研究——基于25省监测点数据的实证分析[J].卫生经济研究,2018,(12):37.
　WU Yu-xia,XU Wei,CAI Gong-jie,et al.Study on the Factors Affecting the Availability of Essential Drugs——An Empirical Analysis Based on Data from 25 Provinces[J].Journal Press of Health Economics Research,2018,(7):37.
[4]李孟林,徐 伟,杜雯雯,等.我国上市专利药品可获得性实证研究[J].卫生经济研究,2019,(12):59.
　LI Meng-lin,XU Wei,DU Wen-wen,et al.Empirical Study on the Availability of Patented Drugs in China[J].Journal Press of Health Economics Research,2019,(7):59.
[5]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17.
　CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(7):17.
[6]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究 ——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8.
　LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province ——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(7):8.

更新日期/Last Update: 2022-06-30